Fig. 1: Biallelic BAP1 mutations result in loss of protein.
From: Concurrent germline and somatic pathogenic BAP1 variants in a patient with metastatic bladder cancer
a Hematoxylin and eosin (H&E) and b BAP1 immunohistochemistry (IHC) showing normal urothelial histology and strong BAP1 nuclear localization, respectively. c H&E and d BAP1 IHC in the proband’s tumor showing loss of protein and weak staining of focal benign stroma cells (black arrows). e External control skin specimen IHC staining from a known BAP1-deficient melanoma (external negative control; red dashed line) and strong immunostaining in neighboring non-malignant tissue (external positive control; yellow dashed line). All representative images were captured at ×200 magnification. Scale bar: 50 μm.
